BROWN RUDNICK LLP for APOTEX CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Trans-Pacific Partnership negotiations relating to drug patent settlements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HENRY W MENN | — |
Health Issues HCR
S. 504 - Fair and Immediate Release of Generic Drugs Act. Electronic Distribution of Content of Labeling for Human Prescription Drug and Biological Products (RIN 0910-A618). Issues relating to Risk Evaluation and Mitigation Strategies.
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.